Premium
Safety of resveratrol with examples for high purity, trans ‐resveratrol, resVida ≫
Author(s) -
Edwards J. A.,
Beck M.,
Riegger C.,
Bausch J.
Publication year - 2011
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/j.1749-6632.2010.05855.x
Subject(s) - resveratrol , chemistry , physics , biochemistry
Studies with resVida ® (a high purity trans ‐resveratrol) show that trans ‐resveratrol is a substance of low oral toxicity. An acceptable daily intake (ADI) in food of 450 mg/day has been defined, a level well beyond natural dietary intake of trans ‐resveratrol. The ADI was based on no‐observed‐adverse‐effect‐levels (NOAELs) of 750 mg/kg bw/day in 13‐week developmental toxicity studies by the dietary route and a standard safety margin of 100. In studies by gavage, the kidney and bladder are target organs at very high dosages (2,000–3,000 mg/kg bw/day). Six‐month studies in rat and rabbit models show no significant increase in toxicity in comparison to 4‐week studies. Lower quoted NOAELs in gavage studies (ca. 300 mg/kg bw/day) potentially reflect more rapid bioavailability, but different dosage regimes complicate comparisons. Short‐term studies show no genotoxicity in vivo . A 6‐month mouse carcinogenicity model showed no increase in tumors. Clinical data support an ADI of at least 450 mg/day, and kinetic data from the DSM 13‐week toxicity study also support the expectation of no increase in toxicity with longer term intake.